Dr. Deborah Dunsire is currently Chair of the Board of Directors of Neurvati Neurosciences, a company dedicated to advancing therapies for neurological and psychiatric diseases. She graduated as a medical doctor from the University of the Witwatersrand in Johannesburg, South Africa. Deborah’s passion is the discovery and development of medicines that transform outcomes for patients. For over 30 years she has built and led companies within the biotechnology and pharmaceutical industry. From 2018-2023, Deborah led Lundbeck, a global company singularly focused on restoring brain health, with products in over 100 countries addressing mental and neurological health. Prior to joining Lundbeck, she was CEO and President of XTuit Pharmaceuticals, focused on inflammatory disease and cancer; FORUM Pharmaceuticals, focused on cognition; and Millennium Pharmaceuticals, focused on innovative medicines for blood cancers and inflammatory diseases.

In addition to chairing Neurvati, she serves on the boards of MCKesson, Ultragenyx, and Syros Pharmaceuticals and Vima Therapeutics. She has been a member of multiple other public company boards in addition to those of the companies she has led, including Takeda Pharmaceuticals in Japan, Allergan, and Alexion. In the course of her career, she has been accountable for the launch of 11 blockbuster medicines, the turnaround of commercial operations, transformation of R&D organizations, and multiple successful mergers and acquisitions. Outside of her work in industry, Deborah serves as a trustee for multiple not-for-profit organizations including Northeastern University in Boston, the International Institute of New England, Whitehead Institute, and the Museum of Science in Boston.